These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 37895937)

  • 1. Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.
    da Silva FC; Brandão DC; Ferreira EA; Siqueira RP; Ferreira HSV; Da Silva Filho AA; Araújo TG
    Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
    Bhat R; Thangavel H; Abdulkareem NM; Vasaikar S; De Angelis C; Bae L; Cataldo ML; Nanda S; Fu X; Zhang B; Schiff R; Trivedi MV
    Sci Rep; 2022 Feb; 12(1):1972. PubMed ID: 35121782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
    Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
    BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance.
    Lin X; Xiang H; Luo G
    Eur J Med Chem; 2020 Nov; 206():112689. PubMed ID: 32829249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer.
    Naeem M; Iqbal MO; Khan H; Ahmed MM; Farooq M; Aadil MM; Jamaludin MI; Hazafa A; Tsai WC
    Molecules; 2022 May; 27(11):. PubMed ID: 35684353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
    Corti C; De Angelis C; Bianchini G; Malorni L; Giuliano M; Hamilton E; Jeselsohn R; Jhaveri K; Curigliano G; Criscitiello C
    Cancer Treat Rev; 2023 Jun; 117():102569. PubMed ID: 37146385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer.
    Alfarsi L; Johnston S; Liu DX; Rakha E; Green AR
    Histopathology; 2018 Oct; 73(4):545-558. PubMed ID: 29603357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
    Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer.
    Rodriguez D; Ramkairsingh M; Lin X; Kapoor A; Major P; Tang D
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
    Brufsky AM; Dickler MN
    Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
    Xia S; Lin Q
    Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
    Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
    Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.
    Yang ZJ; Liu YX; Huang Y; Chen ZJ; Zhang HZ; Yu Y; Wang X; Cao XC
    Cancer Med; 2023 Feb; 12(3):2493-2504. PubMed ID: 35909232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
    Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
    Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen Receptor Signaling in Breast Cancer.
    Miziak P; Baran M; Błaszczak E; Przybyszewska-Podstawka A; Kałafut J; Smok-Kalwat J; Dmoszyńska-Graniczka M; Kiełbus M; Stepulak A
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.